Inclusion Criteria:

- Histologically or cytologically confirmed renal carcinoma

- CT-confirmed metastatic sites

- Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion
measured as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with spiral CT scan

- Disease progression after IL-2

- Age 18 or older

- ECOG performance status 1-3

- Life expectancy ≥ 2 months

- WBC ≥ 3,000/mm3

- Platelet count ≥ 100,000/mm3

- Hemoglobin ≥ 7.5 g/dL

- Creatinine ≤ 1.5 mg/dL (2.0 mg/dL in post-nephrectomy patients)

- Total bilirubin ≤ 1.5 mg/dL

- AST ≤ 3.0 times normal

- Alkaline phosphatase ≤ 2.5 times normal (10 times ULN in presence of bone metastases)

- Not pregnant or nursing

- No history of autoimmune

- No history of serious cardiac arrhythmia, congestive heart failure, angina pectoris,
or other severe cardiovascular disease (i.e., New York Heart Association class III or
IV)

- No CNS metastases by neurologic exam and/or MRI

- No history of seizure disorders

- No local and/or systemic infections requiring antibiotics within 28 days prior to
study entry

- No other malignancy

- Written informed consent